SNYClinical Trials•globenewswire•
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sentiment:Positive (70)
Summary
(NASDAQ:SNY) Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2025 by globenewswire